Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$32.26 – $33.07
Volume40,835
Market cap$301M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$300.83M
Price / earnings
—
Price / book
39.24×
Price / sales
2.69×
EV / sales
2.96×
EV / EBITDA
31.37×
Profitability
Earnings per share
-$0.33
Return on assets
-4.17%
Return on equity
-39.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
6.1×
Current ratio
2.25×
Quick ratio
2.05×
Cash ratio
1.04×
Cash flow
Price / cash flow
40.53×
Price / free cash flow
41.26×
Free cash flow
$7.29M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SMTI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$28.43M
$28.14M
$27.8M
$27.55M
$26.33M
$25.8M
$23.43M
$26.31M
Cost of revenue
$2.1M
$1.98M
$1.92M
$1.87M
$1.87M
$1.94M
$1.83M
$2.25M
Gross profit
$26.33M
$26.16M
$25.87M
$25.67M
$24.46M
$23.87M
$21.6M
$24.06M
Selling, general and administrative
$24.25M
$22.6M
$21.88M
$20.08M
$19.88M
$19.63M
$19.13M
$20.22M
Research and development
$723.72K
$1.15M
$759.59K
$2.04M
$1.03M
$1.06M
$950.36K
$883.4K
Total operating expenses
$25.59M
$24.38M
$23.23M
$24.62M
$21.52M
$21.38M
$20.77M
$21.8M
Operating income
$736.01K
$1.78M
$2.65M
$1.05M
$2.94M
$2.49M
$825.53K
$2.26M
Interest expense
-$1.81M
-$1.81M
-$1.8M
-$1.83M
-$1.82M
-$1.79M
-$1.32M
-$1.29M
Income before taxes
-$1.29M
-$411.14K
$397.69K
-$1.11M
$834.49K
$500.26K
-$620.57K
$934.7K
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.41M
-$452.86K
$458.6K
-$1.61M
-$30.41M
-$2.02M
-$3.53M
-$1.78M
Net income attributable to common shareholders
-$1.41M
-$452.86K
$458.96K
-$1.61M
-$30.41M
-$2.01M
-$3.53M
-$1.54M
EBITDA
$1.35M
$2.4M
$3.23M
$3.56M
$3.98M
$3.6M
$1.95M
$3.87M
Basic earnings per share
-$0.16
-$0.05
$0.05
-$0.19
-$3.52
-$0.23
-$0.41
-$0.18
Diluted earnings per share
-$0.16
-$0.05
$0.05
-$0.20
-$3.40
-$0.23
-$0.41
-$0.18
Recent news
Company coverage with links to the original publishers.
Sanara MedTech reported Q3 2026 earnings of $0.12 per share, beating consensus estimates of $0.06 by 100%, though revenues of $28.43 million missed expectations by 6.48%. The stock has outperformed the S&P 500 by 24.1% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Products industry ranks in the bottom 42% of Zacks industries.
Village Farms reported Q3 2026 earnings of $0.08 per share, beating consensus estimates of $0.05, with revenues of $66.9 million exceeding expectations by 3.94%. However, the stock has underperformed the market by 21.1% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Medical-Products industry ranks in the bottom 41% of Zacks industries, which could limit upside potential.
Cresco Labs Inc. reported a quarterly loss of $0.03 per share, missing the consensus estimate of $0.02 loss, representing a -50% earnings surprise. The company's revenue of $172.78 million slightly missed estimates by 0.54%. With a Zacks Rank #3 (Hold) rating and the Medical-Products industry in the bottom 34% of performance, the stock is expected to perform in line with the market. Shares have declined 53.7% year-to-date versus the S&P 500's 7.4% gain.
MIMEDX Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook. The company announced plans to acquire Sanara MedTech in a transformational combination aimed at creating a leading regenerative medicine company and expanding MIMEDX's surgical footprint across multiple surgical subspecialties.
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether insiders are receiving substantial benefits unavailable to ordinary shareholders and whether transaction terms limit competing offers. The investigations cover Forte Biosciences' sale to argenx, Luxfer Holdings' sale to Wynnchurch Capital affiliates, Sanara MedTech's sale to MiMedx Group, and MarketAxess Holdings' sale to Intercontinental Exchange.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.